HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Brown, S. J. Articles by Dadparvar, S. Search for Related Content PubMed PubMed Citation Articles by Brown, S. J. Articles by Dadparvar, S.

Altered Biodistribution of Gallium-67 in a Patient with Aluminum Toxicity Treated with Desferoxamine

Department of Radiation Oncology and Nuclear Medicine, Division of Nuclear Medicine, Hahnemann University Hospital and School of Medicine, Philadelphia, Pennsylvania

Correspondence: For reprints contact: Steven J. Brown, MD, Hahnemann University Hospital, Div. of Nuclear Medicine, Mail Stop # 309, Broad and Vine St., Philadelphia, PA 19102.

ABSTRACT

Markedly altered biodistribution of [⁶⁷Ga]citrate was observed in a 66-yr-old hemodialysis patient imaged at 48 hr postinjection. A review of the patient's hospital records revealed toxic serum levels of aluminum, treated with the chelating agent desferoxamine. Based on what is known about the biologic interactions between gallium, aluminum, transferrin, and desferoxamine, we believe that both toxic serum aluminum levels and desferoxamine therapy may cause altered biodistribution on [⁶⁷Ga]citrate scintigraphy.